Opinion|Videos|November 16, 2026

Second-Line Sunvozertinib and Dose Selection

Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, asks Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, about sunvozertinib in previously treated EGFR exon 20 insertion–mutated non–small cell lung cancer, where it is approved based on WU-KONG1B and carries a National Comprehensive Cancer Network Category 2A listing but is not yet available.

Lyudmila Bazhenova, MD, of UC San Diego Moores Cancer Center, asks Pasi A. Jänne, MD, PhD, of Dana-Farber Cancer Institute, about sunvozertinib in previously treated EGFR exon 20 insertion–mutated non–small cell lung cancer, where it is approved based on WU-KONG1B and carries a National Comprehensive Cancer Network Category 2A listing but is not yet available. Dr Jänne would prescribe it and stresses the need for options after amivantamab. The approved dose is 200 mg daily in the United States vs 300 mg in China; WU-KONG1B showed similar response and progression-free survival with both, but more adverse events at 300 mg, the dose used in the first-line WU-KONG28 trial. If first-line approval comes, he would start at the 300-mg trial dose and reduce to 200 mg for unmanageable adverse effects. Dr Bazhenova agrees, finds reducing a dose easier than escalating it, and asks companies to routinely publish efficacy by dose reduction.


Related to this article